Animal models of autoimmune disease have been developed that mimic some aspects of the pathophysiology of human disease. These models have increased our understanding of possible mechanisms of pathogenesis at the molecular and cellular level and have been important in the testing, development and validation of new immunotherapies. The susceptibility to develop disease in the majority of these models is polygenic as is the case in humans. The exceptions to this rule are gene knock outs and transgenic models of particular genes which, in particular genetic backgrounds, have also contributed to the understanding of single gene function and their possible contribution to pathogenesis. Gene therapy approaches that target immune functions are being developed with encouraging results, despite the polygenic nature of these diseases. Basically this novel immuno-genetic therapy harnesses the knowledge of immunology with the myriad of biotechnological breakthroughs in vector design and delivery. Autoimmune disease is the result of genetic dysregulation which could be controlled by gene therapy. Here we summarize the genetic basis of these human diseases as well as some of the best characterized murine models. We discuss the strategies for their treatment using immunoand gene therapy. Genes and Immunity (2000) 1, 295-307.
Introduction
The first difference between animal disease models and human autoimmune disease is that in the majority of cases, studies are carried out in inbred mouse strains which express particular major histocompatibility complex (MHC) loci, whilst the human population is outbred and expresses a variety of MHC haplotypes. The role of the MHC in autoimmune diseases appears to correlate with the presence of a particular T cell receptor repertoire 1,2 which will affect the profile of cytokines produced under particular antigenic stimulation of T cells. These important differences affect antigen presentation and T/B cell repertoire in unexpected and unpredictable ways as compared to the animal model studied. A second difference resides in the inducibility of the disease in the majority of animal models by defined antigens, whilst in humans the aetiological agents are unknown. A third important difference is that animal models permit prophylactic or preventive treatment whilst in the clinical setting, patients are diagnosed when disease has already developed and tissue damage has taken place. Lastly but not least, genetic differences between species is also reflected in the presence or absence of certain functional genes from particular cells whose roles in pathogenesis or cell function cannot be underestimated. Caution should be taken therefore when directly extrapolating results from mice to humans. Thus the need and importance of assessing these therapeutic approaches in species other than mice which are more closely related to humans, eg, monkeys.
Autoimmune diseases are chronic, fluctuate in their intensity and develop differently in different individuals. These characteristics make autoimmune disease difficult to manage long term with current available drugs. Also in cases where a therapy appears efficient, such as anti-TNF (tumour necrosis factor) in rheumatoid arthritis (RA) or Crohn's disease, once therapy is terminated the disease often relapses. Thus, in this complex setting gene therapy can provide for long term gene expression, which could also be targeted locally or systemically and possibly in a regulated fashion. Importantly, gene therapy has been shown to be capable of achieving biological effects at least at a thousand-fold lower concentrations than those used for the same gene product as protein. 3 This is an advantage as certain cytokines, which are toxic in bolus protein injections, can be delivered safely and effectively locally by gene therapy.
Up until now most published work in autoimmune disease models have used immuno-therapeutic genes that can induce a shift from a pro-inflammatory (Th1) profile of cytokine production to an anti-inflammatory (Th2) cytokine profile. Most of the investigations carried out up-to-date have been limited to therapeutic assessments for short time periods from 2 weeks up to 4 weeks, with the exception of spontaneous lupus models where therapy has been for 6 months. The use of chronic models of disease should be encouraged.
The great challenge of immuno-genetic therapy resides in its ability to affect specifically pathogenic autoimmune functions, leaving protective immune functions unscathed as they are needed for defense against infectious pathogens.
From the clinical stand point, gene therapy for autoimmune diseases should address not only the immuneinflammatory aspect of pathogenesis but should also attend to the repair of damaged tissue by providing concomitantly immuno-suppressive/immuno-modulatory agents and trophic or growth factors for the impaired tissues.
Multiple sclerosis
In multiple sclerosis (MS), the role of genetic factors have been clearly established from studies with adoptees, monozygotic twins, conjugal pairs and half siblings. 4, 5 Environmental factors have also been demonstrated from studies on migration and apparent epidemics. From all the genetic factors addressed, susceptibility has been clearly established with only certain MHC haplotypes in particular those containing the HLA-DR2 alleles in the Caucasian population whilst in the Mediterranean population links were found with the haplotypes containing HLA-DR4 and HLA-DR3. Other associations with cytokine genes such as TNF␣, IL-1␤, IL-1ra and IFN␥ have not yielded data that are statistically significant, and similarly data examining the TCRB locus, ICAM-1, myelin antigens, myeloperoxidase and chemokine receptor CCR5 (reviewed in Sawcer and Goodfellow 6 ) was inconclusive. The preponderance of the disease in women, points clearly to additional genetic/hormonal factors which are currently poorly understood in MS and in other autoimmune diseases such as RA and systemic lupus erythematosus (SLE).
Vaccination with T-cell receptor (TCR) peptide from the V␤5.2 sequence expressed in MS plaques and on myelin basic protein (MBP)-specific T cells has been tried in MS. Individuals responding to TCR vaccination, as assessed by T cell clone frequencies to the peptide, had a slight decrease in the number of MBP-specific T cell clones frequencies. This lower MBP response correlated with stable disease or slight improvement and increased IL-10 secretion by TCR-specific T cell clones. 7 Some key studies have established the beneficial clinical effect of IFN␤ in the treatment of MS and clinical effects are accompanied by changes in MRI-scans and cytokine profiles towards an anti-inflammatory phenotype, ie, more IL-4 and IL-10. 
Experimental allergic encephalomyelitis
In the mouse models of MS, ie, experimental allergic encephalomyelitis (EAE) and chronic relapsing experimental allergic encephalomyelitis (CREAE), crosses between susceptible and resistant strains to develop EAE or CREAE 9 after immunization with myelin antigens and using congenic strains, have identified several genetic loci located in the MHC class II cluster (chromosome 17) and outside of it on chromosomes 3, 7 and 15. Levels of expression of cytokines are associated with disease susceptibility or resistance. 10 Epistatic effects were also demonstrated between chromosomes 4, 8, 11 and 17.
Using a different pathogenic agent, ie, Theiler's murine encephalomyelitis virus (TMEV), EAE susceptibility loci have been found on chromosomes 17 (in this case the MHC class I cluster), 3, 6 and 10 (reviewed in Holmdahl 11 ). These results indicate that different EAE susceptibility genetic loci could be involved depending on the aetiologic agent but some other genes such as those located on chromosome 3 could be involved independently of the environmental trigger of the disease. Interestingly, chromosome 3 has also been linked to susceptibility to collagen-induced arthritis (CIA) and nonobese diabetes (NOD).
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During persistent chronic infection with TMEV, CNS autoimmunity could develop as result of epitope spreading to proteolipid protein (PLP) 12 but also due to molecular mimicry between TMEV structural proteins and myelin basic protein. 13 From studies in autoimmune demyelinating disease the following general conclusions have been drawn: there may not be a single target autoantigen, diverse peptide self determinants from multiple myelin proteins can be recognized, determinant epitopes may differ among different individuals and target epitope recognition can change with time during the course of disease.
14 It is most probable that the same conclusions could be applied to many other autoimmune diseases. It is unlikely that therapies targeting a particular TCR chain or immunogenic peptide will prove efficient on a wide outbred human population. However other well conserved molecules such as co-stimulatory molecules, cytokines and soluble cytokine receptors (of antagonistic action) if delivered in the appropriate context of time and space (locally) could prove more specific despite their intrinsic pleiotropic effects.
Immunotherapies of EAE
Co-stimulatory molecules on T cells and antigen presenting cells have been targeted successfully with antibodies to treat EAE. Antibodies specific for B7, 15 CD4, MHC class II have been used as well as pro-apoptotic molecules such as galectin-1. 16 Cytokines have been blocked using antibodies such as anti-TNF 17 and tolerance has been restored by feeding MBP 18 and cholera toxin conjugated to MBP. 19 For reviews on cytokines in inflammatory brain lesions see references 20 and 21. Intranasal administration of mutated MBP-specific peptides 22, 23 and oral administration of PLP peptides 24 have been pursued in order to restore tolerance to myelin antigens.
Transgenics/gene knockout (K.O.) mice Surprisingly, mice with a disrupted IFN␥ gene are susceptible to EAE indicating that this cytokine is not essential for some of the development of its pathology. 25 Mice expressing TNF␣ in the central nervous system (CNS) spontaneously develop chronic inflammation and demyelinating disease with 100% penetrance. Systemic treat-ment with anti-TNF in this model prevented development of neurological symptoms (ie, imbalance, seizures, ataxia, hind limb paresis), microgliosis, T cell infiltration to CNS parenchyma and demyelination. 26 A double transgenic mouse expressing rearranged TCR genes (V␤8.2 and V␣2.3/J␣), specific for MBP, developed spontaneous EAE in non-sterile conditions but did not when maintained in sterile pathogen-free environment. 27 IL-6 expressed in the CNS from the glial fibrillary acidic protein gene promoter, causes neurologic disease. Mice with higher levels of expression showed severe disease characterized by tremor, ataxia, seizure and runting. Histological findings included astrocytosis, angiogenesis and neuro-degeneration. 28 IL-6 deficient (−/−) mice are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE. 29, 30 This is not for lack of encephalitogenic cells as transfer of IL-6 +/+ T cells cannot induce disease consistent with IL-6 functioning at the perivascular inflammatory process. The potent Th1 cytokine IL-12 unmasks latent autoimmune disease in resistant mice. 31 Fas and Fas-L deficient mice do not develop EAE. 32 An antibody mediated model of demyelination was inhibited by soluble CR1 (CD35). 33 Encephalitogenicity of T cells correlates with production of LT (lymphotoxin) and TNF in MBP-specific T cell clones. 34 Transgenic anti-MOG Ab accelerates and exacerbates disease after induction. 35 Mice lacking nitric oxide synthase 2 (NOS2) have exacerbated EAE, 36 IL-4 deficient mice develop EAE and can spontaneously recover whilst IL-10 deficient mice develop accelerated EAE and fail to recover.
37 Surprisingly, TNF −/− mice do develop EAE 38 but as pointed out, 39 cytokine effects are local and temporal and biological results from K.O. mice have to be assessed in view of additional studies performed with anti-cytokine antibodies and local vs systemic cytokine administration. CD40 −/− mice are also resistant to EAE, 40 CD8 −/− have less mortality but more relapses of EAE, 41 CD4 −/− mice develop EAE and an expanded double negative population may replace helper and effector functions. 42 
Gene therapy in EAE
Both ex vivo and in vivo gene therapy has been used to treat CNS diseases. Direct CNS injections of plasmid DNA vectors expressing IL-4, IFN␤ both from a retroviral promoter or from a neuron specific enolase promoter, TGF␤ and dimeric soluble TNF-R were potent inhibitors of EAE when injected intracranially 10 days post immunization. 43 CNS injection of adenovirus expressing CTLA4-Ig ameliorated significantly the development of EAE without inhibiting peripheral immune responsiveness. 44 Immunization with TCR 45 was protective for EAE. Engineering IL-4-producing MBP-specific T cell hybridoma, 46 encephalitogenic T cells expressing IL-4 (Croxford et al unpublished) or encephalitogenic T cells engineered to express TGF␤ 47 were shown to affect ongoing EAE immune responses and inhibit disease. Fibroblasts expressing soluble dimeric p75 TNF-R, when implanted intracranially, could inhibit both the acute and the relapse phase of EAE. 48 Any cell type to be used for the delivery of therapeutic genes into the CNS will be better suited to that millieu possibly if it originated from it. Such CNS-derived cell (such as oligodendrocytes, microglias or neurons) could also secrete other trophic factors necessary for tissue
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Systemic lupus erythematosus
SLE is an autoimmune disease where the humoral response is clearly dysregulated and auto-antibodies to several cellular structures have been well characterized. Links between MHC genes and the presence of antibodies to particular antigens have been described. For example anti-Ro and anti-La antibodies have been associated with the presence of HLA-DR2 and HLA-DR3, anti-lipid antibodies have been linked to HLA-DR4, HLA-DR7 or HLA-DQ7, anti-Sm and anti-nRNP antibodies have been associated with HLA-DR4 and HLA-DQ3. Deficiency in complement components has been consistently reported has a susceptibility factor for SLE. Deficiencies in C1q, C2 and C4 develop SLE with frequencies of 90%, 33% and 75% respectively (reviewed in Harley et al 49 ). This correlation suggests that impaired processing of immune complexes is implicated in the pathology of this condition.
Linkage analysis studies have found susceptibility loci on chromosomes 1, 13, 14, 16 and 20. Interestingly, the marker on chromosome 16 is close to a susceptibility marker for psoriasis, Crohn's disease and Blau syndrome. Associations were found outside the MHC complex with the Hsp70-2 and prolactin gene respectively in African Americans and British population. 50 Fas/APO-1 mutations 51 and a particular genotype of the Fc␥ receptor are associated with SLE.
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Animal models of SLE The F1 hybrid cross between New Zealand black (NZB) and New Zealand white (NZW) mice is generally regarded as the murine model most closely resembling human SLE. The disease is spontaneous, more severe and develops earlier in females (at ෂ4-5 months of age) 53 ; high titres of IgG anti-DNA antibodies, antinuclear antibodies (ANA) occurs in virtually all females and death results from progressive glomerulonephritis. 54 The disease in the BWF1 mouse is particularly sensitive to the effects of sex hormones; in general, androgens are protective and suppress the production of autoantibodies whereas estrogens are permissive. 55, 56 Both NZB and NZW parents contribute genetically to the immune abnormalities that cause disease. The NZW parent has a slightly shortened life span compared with other normal mice and has a large portion of the T cell receptor ␤ chain locus deleted. 57, 58 The BWF1 mouse also inherits B cell hyperactivity characteristic of the NZB parent, with abnormally high secretion of Ig detectable by 1 month of age. 59 However, the T cell dependence of the B cell response is more striking than the NZB parent, and is probably responsible for the isotype shift from IgM anti-DNA to IgG anti-DNA that precedes clinical disease. 60 T cell involvement in the production of anti-double stranded DNA (dsDNA) antibodies in this mouse, as in human SLE, is apparent from their IgG isotype, the presence of somatic mutations in the antibody genes and by experiments showing that Abs to Thy-1 or CD4 blocked Abs production and development of the disease. 61 The anti-dsDNA antibodies are mainly of the IgG2a isotype and their production is therefore, presumably, dependent upon the Th1 subset of CD4 + T cells. 62 It remains unclear, however, how CD4 + T cells, which recognise peptide-MHC complexes, provide help for B cells to produce Abs to dsDNA. Proposed mechanisms include T cell recognition of DNA-associated histones, recognition of peptide fragments of IgG anti-dsDNA auto-Abs or T cells recognition of CD1, an invariant MHC class I-like molecule expressed on a subset of B cells.
Breeding between NZB and NZW strains has given rise to several strains called NZM which contain different amounts of their genome derived from either NZB or NZW. The NZM2410 strain which inherits most of its genome from the NZW origin develops glomerulonephritis with a penetrance of 85% and a mortality of 50% by the age of 6 months irrespective of sex. This indicates that several parameters such as onset and severity of disease have changed in the NZM2410 strain. Using more than 7000 polymorphic micro-satellite markers several susceptibility loci have been mapped to all mouse chromosomes with the exception of chromosomes 8, 12 and 15. Recent work has also found the presence of recessive loci responsive to resistance to the disease. 53 Thus this model fits very well with the definition of a polygenic disease.
The SNF1 mouse is produced by cross mating of NZB mice with the normal SWR mouse. 63 In contrast to NZW, which can develop mild nephritis late in life, the SWR1 mouse is completely healthy and has a normal life span. Clinically, the SNF1 mouse is similar to BWF1 mice, with most females dead by 10-12 months and with a 50% mortality rate at 6 months of age with an immune glomerulonephritis that is mediated primarily by IgG2b antibodies to DNA. 64 This model has been of particular interest because of the oligoclonality of the cationic IgG anti-DNA deposited in the kidney. Disease expression in SNF1 mice requires T cell help, and B cells from the spleen of these mice secrete IgG2b antibodies only when stimulated by T cells in culture. 65 The T cells involved in this disease are CD4
+ that bear ␣␤ TCR and double negative CD4 CD8 T cells expressing ␥␦TCR. 66 This contrasts with the MRL/lpr mice in which the lymphoproliferating T cells are double CD4 CD8 negative but with ␣␤ TCR. 67 As in the BWF1 mouse, susceptibility to disease in the SNF1 mouse is multigenic in nature with genes contributed from both parents being necessary for disease development. Some genes are clearly linked to MHC genes. However, some studies also suggest that nephritis is influenced by the TCR ␤ chain locus, which contains a large deletion similar to the NZW mouse, as well as I-A ␤ chain of the SWR parent. 68 The MRL/LPR/lpr (MRL/lpr) mice were originally derived from LG/J mice crossed with AKR/J, C3Hdi and C57Bl/6 mice. Studies have revealed that the lymphoproliferative (lpr) trait occurs as a result of mutation in the Fas gene. One of Fas functions is the control of apoptosis. 69 The mutation in Fas causes massive lymphoproliferation in virtually all recipients. Both male and female MRL/lpr mice develop high serum levels of immunoglobulins, monoclonal paraproteins, ANA and immune complexes. 54 The mice produce IgM and IgG anti-DNA and die from immune nephritis at a young age (90% dead by 9 months). The mice also produce other autoantibodies including IgG2a anti-chromatin, anti-red blood cells, anti-thyroglobulin, anti-Sm, anti-RNA polymerase and rheumatoid factors autoantibodies. 70 The MRL/lpr differ from New Zealand mice hybrids in that they develop: (1) massive lymphoproliferation, (2) destructive inflammatory arthritis, (3) produce rheumatoid factor and anti-Sm autoantibodies. 71 In females, anti-DNA antibodies are detectable in the serum by 6-8 weeks of age, proteinuria begins at 1-3 months and death associated with azotemia begins at 3-6 months, males lag behind by approximately 1 month. Despite these abnormalities, however, lymphoid malignancies are rare in these mice. As in the New Zealand hybrid models, the disease in the MRL/lpr mouse is T cell dependent, with the lpr gene conferring characteristics of increased proliferation and probably providing help for B cells to make autoantibodies. Indeed T cell help for syngeneic B cells is more marked in MRL/lpr mice than in BWF1 mice. 71 The ability of T cells in MRL/lpr to cap, proliferate, express IL-2 surface receptors and produce IL-2 after antigenic or mitogenic stimulation is impaired. 72 Some studies suggest that this may be due to deficient signalling via the phosphoinositide pathway. 73 Furthermore, studies suggest that the T cells are unable to cause activated B lymphocyte apoptosis due to a failure to signal through the mutated Fas gene in B cells. Genetic analysis of disease in relation to the development of arthritis and of anti-Sm antibodies has shown that up to ෂ25% develop one or other of these manifestations depending on the colony and without known genetic factor. 54 This observation suggests that unknown environmental factors may be responsible for the development of these features.
Transgenics and knockout mice models of lupus
The severe nature of lupus disease and resulting inflammatory lesions in the spontaneous animal models described above have precluded conclusive identification of the primary and secondary autoimmune events that initiate disease. Targeted mutations of genes that function in immunity have been generated by backcrossing knockout mice onto autoimmune-prone backgrounds (MRL/lpr background in the vast majority of studies) and the data have been of great value in identifying important aspects of lupus disease pathogenesis. 74 Mice made deficient in B cells or T cells have reduced renal disease and increased survival rates. 75, 76 In addition, these studies have revealed that the role of B cells in lupus goes beyond the production of autoantibodies and that the contribution of these cells involves also antigen presentation to, and activation of, autoreactive T cells among other things. 74 Deletion of MHC class II, but not class I, genes have also been shown to have a significant effect on autoantibody production and kidney lesions. 77 Intriguingly, whilst mice deficient in ␣␤ TCR + T cells developed a mild disease, MRL/lpr mice deficient in CD40 ligand (CD40L) did not develop glomerulonephritis and did not produce autoantibodies of the IgG isotypes. 78 This finding may indicate that the CD40-CD40L complex is involved in the development of glomerulonephritis by other mechanisms in addition to its role in B and T lymphocyte priming. More recent studies of knockout mice showed that ablating IFN-␥ or IFN-␥ receptor has a significant ameliorating effect on the disease process in lupus-prone MRL/lpr mice. 79, 80 In contrast to these gene knockouts on lupus-prone back-grounds, C1q-deficient mice develop higher titres of autoantibodies, compared with strain-matched controls and have a decreased life span. Of the C1q knockout mice ෂ25% develop glomerulonephritis with immune deposits and multiple apoptotic cell bodies in the glomeruli. 81, 82 These findings are compatible with the theory that complement deficiency can contribute to autoimmunity, possibly by impairment of the clearance of apoptotic cells.
Immunotherapy of SLE
A large number of studies have been conducted over the last two decades to treat lupus nephritis in animal models of disease by immunotherapy. Initially, studies using antibodies to Thy-1 or to CD4 have decreased autoantibody production and reduced lupus nephritis. 61 More recently, a number of investigators have successfully used blocking antibodies to CD40L. 83 Interestingly, these studies have shown a clear diminution of responses to nuclear antigens that lasted beyond the half-life of the antibody, implying perhaps that tolerance could be achieved if anti-CD40L antibody is applied during the early phase of the autoimmune response. In addition to targeting T and B cells, a number of studies have either blocked individual cytokines or applied recombinant cytokines. These studies have shown that a number of cytokines interact with each other to increase or decrease the level of autoreactivity in diseases. In this respect, it is noteworthy that TNF␣ and IL-10 have a reciprocal relationship in the BWF1 mouse, with striking effects on the expression of the autoimmune phenotype. 84, 85 Early studies with TNF␣ revealed that administration of weekly non-toxic doses of recombinant TNF␣ to adult BWF1 mice (16 weeks of age) for 4 months markedly delayed the onset of lupus nephritis while neutralising doses of anti-TNF␣, significantly hastened the onset of nephritis. 84 More recent experimental data by Ishida et al 85 showed that frequent injections of anti-IL-10 antibody to young adult BWF1 mice resulted in a significant delay in the onset of nephritis and death. Because of the previously described effects of TNF␣ on nephritis in this strain and because IL-10 suppresses macrophage functions, such as TNF␣ production, these experiments were repeated with simultaneous administration of anti-TNF␣. When both anti-IL-10 and anti-TNF␣ were administrated, there was no delay in the onset of nephritis and renal failure. Inhibition of complement with anti-C5 in the NZB/NZW had a protective effect.
86
Gene therapy in lupus Intramuscular injections of TGF␤ DNA, at monthly intervals for 6 months, were used therapeutically in the MRL/LPR/lpr mouse. This treatment produced a decrease in kidney fibrosis and retarded the development of hypergammaglobulinemia whilst injection of IL-2 DNA had the opposite effects. 87 The fact that TGF␤ was an effective therapy is extremely important as TGF␤ is considered to be the cause of kidney fibrosis. It could be argued that the physiology of the kidney is altered by deposition of antibody complexes which in turn activate proteolytic cascades leading to the activation of TGF␤. These putative proteinase cascades could therefore provide an appropriate therapeutic target for future studies. Recent research, has shown that indeed the activation of thrombin could mediate renal inflammation in crescentic glomerulonephritis. 88 Therefore it could be appropriate
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Diabetes
Diabetes affects about 0.3% of the Caucasian population. 90 Glutamic acid decarboxylase (GAD) appears to be an important antigen driving the autoimmune response in Type I diabetes and in animal models of the disease. 91 Susceptibility to insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) has been clearly shown to be linked to the presence of MHC class II HLA-DR3 or HLA-DR4 by serological studies whilst presence of HLA-DR2 (in particular HLA-DR2-HLA-DQ*0602) and some other HLA-DR4 subtypes have a protective effect. 92 With the introduction of polymerase chain reaction analysis of DNA sequences, it was determined that in Caucasian diabetic patients the HLA-DQ␤1 chain has a non-acidic amino acid at position 57 which is normally occupied by an aspartic acid residue in the unaffected population. [93] [94] [95] [96] A genome screen using 290 markers for loci spaced about 11 cm from each other, linkage was found with the MHC (chromosome 6p), insulin gene (chromosome 11p). Other genes outside the MHC are also being implicated in diabetes complications such as the angiotensin-converting enzyme (ACE) in nephropathy, 97 hypertension [98] [99] [100] [101] [102] and obesity.
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Animal models of IDDM As in human IDDM, in the of the non-obese diabetic (NOD) mouse spontaneous model, disease is linked to a variety of genes both within 107 and outside the MHC. [108] [109] [110] Using the NOD genetic background, several studies have assessed the role of the immune system and of cytokines in disease progression or treatment. The T cell autoimmune response in IDDM is in part directed to GAD 91 and B cells are necessary antigen presenting cells for the immune response to GAD. 111 Transgenic mice expressing different genes from the insulin promoter have clearly established the pathogenic potential of pro-inflammatory cytokines such as IFN␥ 112 and TNF/lymphotoxin 113, 114 whilst a protective effect has been seen by pancreatic expression of IL-4. 115, 116 TGF␤ expression in the pancreas conferred protection from diabetes by polarizing antigen presentation by dendritic cells to a Th2 phenotype. 117 TNF-R1 and perforin have been implicated in islet ␤ cell destruction. 118, 119 A study by Pakala et al 120 has clearly demonstrated that TNF also affects the physiology of the ␤ cell and TNF plays a role in obesity. 121, 122 Thus cytokine therapy should be viewed as affecting not only the immune system but also the physiology of the target organ due to the pleiotropic properties of cytokines whose receptors are widely distributed in different tissues.
IL-10 has given conflicting results when expressed in the pancreas and appears to mediate insulitis via effects on CD8 + cells. 123 Diabetes could be induced after Coxsackie virus infection, indicating the importance of environmental factors.
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Immunotherapies of IDDM Anti-CD3, 125 anti-CD4, CTLA4-Ig, IL-4 and IL-10 have been used with varying degrees of success. TNF may have different roles depending on the age of the treated animals. 114 Anti-TNF treatment from birth to 2 weeks prevented IDDM, whilst it could delay disease onset if treatment was initiated after 4 weeks of age. Administering GAD prevents IDDM 126 whilst regulatory GADspecific T cells can inhibit ongoing diabetes. 127 Antibodies against VLA-4 and L-selectin inhibit insulitis and IDDM.
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Gene therapy of diabetes Using pathogenic T cells modified to express therapeutic immunomodulators has proven to be an efficient mean to target specific organs. In the NOD model, diabetogenic Th1 T cells were modified to express IL-10 under the IL-2 promoter. 129 Also diabetogenic T cells engineered to express IL-4 with a retrovirus (Yamamoto A-M et al in preparation) prevented transfer of IDDM to severe combined immunodeficient (SCID)-NOD mice, these engineered cells were shown to protect islet destruction and home to the pancreas. In order to protect islet grafts, Fas expressing cells such as engineered myoblasts 130 or testicular cells 131 have been co-implanted and shown some level of protection. However, this approach has not worked for others. 132 Intramuscular injection of naked plasmid expressing insulin was used to ameliorate effectively streptozocin-induced diabetes in BalbC mice. 133 Recent advances in the growth of pancreatic stem cells 134 may prove essential for the cure of this disease. These in vitro generated cells may need to be encapsulated before their use in vivo to prevent destruction by the already activated immune system. The possibility of engineering pancreatic stem cells to express immunosuppressive genes may increase their long-term viability, as antibodies to pancreatic antigens may cause transplant dysfunction over time.
Rheumatoid arthritis (RA)
RA is a chronic inflammatory disease which involves lymphocyte and macrophage infiltration into joints as well as the presence of rheumatoid factors in serum. Cartilage degradation is accompanied by the outgrowth of the synovial membrane (pannus) that overproduces metalloproteinases induced by the high levels of TNF and IL-1. The imbalance of cytokines has been well characterized 135 and the high levels of pro-inflammatory cytokines counteract the presence of inhibitory cytokines such as TGF␤, IL-10 or cytokine inhibitors such as soluble TNF receptors (TNF-Rs). Susceptibility to RA has been mainly correlated with the MHC class II locus in particular with HLA-DR4 [136] [137] [138] [139] which is associated with severity of disease and some association was found also with the class III locus. 140 Immunotherapies for RA have examined the effects of inhibiting the inflammatory TNF-driven cytokine cascade using anti-TNF antibody 141 or TNF-R-Ig fusion proteins. 142 TNF was shown in vitro to inhibit IL-1 production 143 and mice lacking IL-1 develop a milder type of arthritis. 144 The cartilage destructive properties of IL-1 have been targeted by inhibition using either IL-1ra or a soluble IL-1 receptor fusion protein. 145 In general, anti-T cell therapies such as anti-CD4 146, 147 have been disappointing until now but this may be due to the particular epitopes of CD4 which are targeted by these particular antibodies.
Clinical trials using vaccination with T cell receptor (V␤ 3, 17 and 14) peptides is currently under way. 148 
Animal models of arthritis
The most widely used model of RA is the collageninduced arthritis (CIA) model in DBA/1 mice 149 which has both a cellular and humoral component. 150 The MHC has an important role in the susceptibility and resistance to CIA. 149 It appears that local TNF is the driving force behind the chronic inflammation as it has been elegantly shown in arthritis models in transgenic and null mice where the immune system does not play an important role. [151] [152] [153] [154] On the other hand it has also been shown that TNF plays an important role in the maturation of B cells and the formation of germinal centers 155 in mice. A chronic arthritis model has been developed by backcrossing a TCR V␤12 transgenic onto the DBA/1 background. 156 An antigeninduced arthritis model in rabbits has been widely used also for local therapy. The animals are firstly immunized with ovalbumin and complete Freund's adjuvant and then a delayed type hypersensitivity reaction is triggered in the joint by injecting ovalbumin in the synovial space.
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K.O. mice in arthritis
As in EAE, IFN␥ or IFN␥-receptor 158, 159 genes do not appear to be essential for the development of arthritis. Moreover, these mice develop a different more accelerated arthritis. However, IL-6 −/− mice develop mild CIA with a delayed onset. 
Immuno-therapies in arthritis
In animal models of disease treatment with anti-CD4 antibody has shown encouraging results 156, 161 and synergistic effects were reported when used in combination with anti-TNF. 162 Anti-gp39 (CD40L) was very effective and also decreased the anti-collagen antibody titres in collagen-induced arthritis. 163 Anti-C5 164 was therapeutic and intranasal administration of cholera toxin-collagen prevented CIA. 165 Other reported treatments include: anti-CD23, 166 IL-4, 167 IL-11 and IL-10, [168] [169] [170] anti-IL-12 171 and combination of anti-IL12 with anti-TNF. 172 In the rabbit antigen induced arthritis model, proteolytic degradation of cartilage was ameliorated by intraarticular injection of a viral serine proteinase inhibitor SERP1, 173 in a rat model of mono-articular arthritis soluble CR1 suppressed inflammation. 174 Antibody therapy to inhibit oncostatin M ameliorated significantly established arthritis in CIA and in a pristane-induced model. 175 Blocking of TCR and MHC interactions was achieved with collagen peptide bound to soluble MHC on an Ig backbone.
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Gene therapy in arthritis Ex vivo engineering of synoviocytes with retrovirus expressing IL-1ra followed by their implantation in arthritic joints was used to ameliorate antigen-induced arthritis in rabbits. 157 The same protocol was utilized in a clinical study in RA. 177 Other approaches have included the direct injection in the joint of IL-1ra expressing retrovirus 178 or in vivo injection of Chinese hamster ovary (CHO) cells expressing IL-4 and IL-13. 179, 180 Using these xenogeneic cells, these authors have been able to reduce levels of TNF expression in transgenic mice expressing TNF. 181 Galectin-1 was delivered constitutively by syngeneic fibroblasts implanted intraperitoneally. Galectin-1 induced antigen-specific T cell apoptosis and also provoked a clear switch to a Th2 cytokine profile production. 3 Using the same delivery system, a novel TNF antagonist 182 and IFN␤ 183 were shown to be of clinical benefit at different stages of disease development.
Based on the principle of arthritis transfer by T lymphocytes 184 and from previous attempts to direct therapeutic genes to tumours using tumor infiltrating lymphocytes (TILs) 185 we have used arthritogenic T cells to deliver gene products to joints. Arthritogenic T cells were modified with retroviruses expressing soluble TNF receptors 186, 187 or TGF␤ 188 and shown to be capable of downregulating established disease, and inducing changes in the B cell compartment as assessed by inducing an Ig isotype switch from IgG2a to IgG1 which reflects changes in Th cytokine production. The combination of both TGF␤ and dTNF-R had an increased biological effect. 182 The inflamed synovium has been directly targeted in vivo with retrovirus, adenovirus, plasmids complexed with cationic lipids and DNA oligonucleotides serving as decoys for NFkB. [189] [190] [191] [192] Interestingly, in vitro infection of rheumatoid synovial cells with adenovirus expressing an inhibitor of NFkB (IkB␣) has shown that T cells, fibroblasts and macrophages could be infected and was capable of down-regulating expression of inflammatory cytokines whilst sparing the expression of protective cytokines. 193 These findings are of interest as normally T cells or macrophages are non-permissive to adenoviral infection and indicates that these cells exist in the rheumatoid joint in a different physiological state than normal cells. Adenovirus injection to the inflamed joint has been performed using IL-1ra , sIL-1 receptor and sTNF-R, 194 sFas-L 195 as transgenes. Recently IL-1ra was also delivered using herpes simplex viral vector. 196 Intramuscular injection was therapeutic using TGF␤ 197 and also with a dimeric form of soluble CR1 (CD35) on an Ig backbone (Dreja et al in preparation). Vaccination with a TCR gene overexpressed in arthritis could prevent development of CIA. 198 Using pluripotent mesenchymal cells engineered to express BMP-2 (bone morphogenetic protein-2), it was possible to enhance bone repair in vivo. 199 T lymphocytes appear to be suitable cells for carrying therapeutic genes due to their exquisite specificity, long half-life, capability to cross endothelial barriers and their proliferation upon encounter with antigen. Antigenspecific lymphocytes will amplify the therapeutic effect locally where the antigen is being presented.
In a clinical setting, where epitope spreading occurs as a dynamic process, it is very difficult to define at a particular time point which antigen(s) drive the autoimmune response allowing the growth and expansion of arthritogenic T cells, as was done in the animal model. For this reason we have decided to engineer T cells to recognize collagen type II so that they will target joints. It is expected that due to the ongoing inflammation these engineered T cells will reach these joints, became activated in situ, and deliver their therapeutic gene product as we previously reported when using syngeneic arthritogenic T cells. In order to achieve this we grafted T cells with a chimeric receptor composed of an extracellular domain from a collagen type II specific monoclonal antibody (as a scFv ) and a signalling domain of TCR sub-units. As signalling subunits we have used either the Fc⑀R1 ␥-chain 200 or the TCR chain. 201 These chimeric receptors enable T cells to recognize unprocessed collagen type II in an MHC-independent manner and respond by secreting cytokines and proliferating as expected.
Overall gene therapy of arthritis has been leading the way in the use of relevant immuno-suppressive and antiinflammatory therapies in autoimmune disease. This is possibly due to the better understanding of the pathogenic mediators in this disease, ie, cell types, cytokine hierarchy, metalloproteinases due to the accessibility of the tissue for study. However the use of mesenchymal stem cells that will replace and repair the damaged cartilage and bone still needs further efforts.
Similarities and differences in autoimmune diseases and possible future interventions
As mentioned previously, the immune system functions as an entire entity. Each of the different compartments, both natural immunity (complement, natural antibodies) and adaptive immunity (antigen presenting cells, T and B cells), play roles of greater or lesser importance at different stages in different autoimmune diseases. It has been clearly shown by the immunotherapy and gene therapy studies, described above, that affecting one compartment has an effect on the other. Thus blocking T cells affects B cells and affecting the complement cascade also has implications on T and B cell differentiation and function. These effects have been shown in particular in CIA but also in EAE, lupus and the NOD mouse model. Overall, targeting the pro-inflammatory response with inhibitory cytokines (such as IL-4, IL-1ra, TGF␤ and IFN␤) or with cytokine-inhibitors (such as anti-cytokine antibodies, soluble cytokine receptors) important biological therapeutic effects have been obtained. Nevertheless, the mechanisms of action of the different therapies are not yet fully understood. In general, it seems that common immune mechanisms are involved in all autoimmune diseases despite their polygenic nature. The chronic nature of these diseases will need to be taken into consideration for the development and use of non-immunogenic vectors (such as retroviruses), methods of gene expression which will be regulated (such as the tetracycline regulated system [202] [203] [204] ) and must be active only at relapse or flares of disease. Gene regulation is of paramount importance as indiscriminate long-term expression of biologicals could compromise important immune functions. The possibility of using encapsulated cells in retrievable devices could be considered. 205 In severe cases of autoimmune disease, total body irradiation and autologous bone marrow transplantation (BMT) has been considered. 206, 207 BMT has been shown to work experimentally in models of arthritis. 208, 209 However in certain cases this approach may not work as susceptibility to disease development may be carried with cells of the bone marrow themselves as shown in the NOD mouse. 210, 211 The most important difference between autoimmune diseases resides in the organ targeted by the immune system and therefore trophic or growth factors necessary for tissue repair may need to be different in different dis-eases. It is plausible that in the future, combination gene therapy will include immuno-modulatory gene products as well as the appropriate trophic gene factors for each tissue. Moreover, recent advances in methods for growing stem cells from different tissues will enable transplantation and partial or total organ replacement. These cells could be engineered ex vivo with immuno-modulatory genes that will prevent the activation of the immune system and destruction of newly implanted cells.
